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Fenoﬁbrate is mainly used to reduce cholesterol level in patients at risk of cardiovascular disease.
Thermal transition study with the help of differential scanning calorimetry (DSC) shows that the
aforesaid active pharmaceutical ingredient (API) is a good glass former. Based on our DSC study, the
molecular dynamics of this API has been carried out by broadband dielectric spectroscopy (BDS) covering
wide temperature and frequency ranges. Dielectric measurements of amorphous fenoﬁbrate were per-
formed after its vitriﬁcation by fast cooling from a few degrees above the melting point (Tm¼354.11 K) to
deep glassy state. The sample does not show any crystallization tendency during cooling and reaches the
glassy state. The temperature dependence of the structural relaxation has been ﬁtted by single Vogel–
Fulcher–Tamman (VFT) equation. From VFT ﬁt, glass transition temperature (Tg) was estimated as
250.56 K and fragility (m) was determined as 94.02. This drug is classiﬁed as a fragile glass former.
Deviations of experimental data from Kohlrausch–Williams–Watts (KWW) ﬁts on high-frequency ﬂank
of α-peak indicate the presence of an excess wing in fenoﬁbrate. Based on Ngai's coupling model, we
identiﬁed the excess wing as true Johari–Goldstein (JG) process. Below the glass transition temperature
one can clearly see a secondary relaxation (γ) with an activation energy of 32.67 kJ/mol.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
To increase the solubility and bioavailability of the poorly water
soluble crystalline drugs is a challenge to modern pharmaceutical
scientists. One of the promising methods for improving solubility
and bioavailability of poorly water soluble crystalline drugs is to
prepare them in the amorphous form. Amorphous form of phar-
macologically active materials is very important because this form
has enhanced thermodynamic properties, having high internal
energy, solubility, bioavailability, dissolution rate, better com-
pression characteristics and greater therapeutic activity than the
corresponding crystalline counterpart [1–4]. However, amorphous
systems are physically and chemically unstable and therefore
show crystallization tendencies.
Recent studies on various amorphous pharmaceutical drugs
show that molecular mobility above and below the glass transition
temperature (Tg) plays an important role in the devitriﬁcation of
the drugs. The knowledge about the molecular dynamics of theon and hosting by Elsevier B.V. Th
University.
ja).drugs in the amorphous phase is very important for safety storage
in order to obtain the maximum shelf-life and stability [5–8].
Fenoﬁbrate had been chosen as a model drug for the current
study. It is a ﬁbric acid derivative which has greater high density
lipoprotein cholesterol (HDL-CH) rising and greater low density li-
poprotein cholesterol (LDL-CH) lowering action than other ﬁbrates
[9]. To the best of our knowledge, this will be the ﬁrst attempt to
describe the dielectric relaxation study of amorphous fenoﬁbrate.
For this it is essential to have a better understanding of mole-
cular dynamics in supercooled and glassy state of this API. In the
present study, we used differential scanning calorimetry (DSC) for
thermal transition analysis and observed that fenoﬁbrate is a very
good glass former. Based on DSC study, dielectric measurements of
this API were carried out by broadband dielectric spectroscopy
(BDS) as an investigative tool to study the molecular dynamics of
amorphous systems in a wide range of frequencies (f¼109–
102 Hz) at different thermodynamic conditions (P, T). Recently
this technique has been successfully applied to study the mole-
cular dynamics of various amorphous pharmaceuticals [10–12]. To
get a clear picture of hydrogen bonding in the crystalline and
amorphous state of fenoﬁbrate, infrared (IR) spectroscopy was
used.is is an open access article under the CC BY-NC-ND license
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2.1. Material
Fenoﬁbrate, a white crystalline powder CAS no. 6271-86-2, was
supplied by Sigma Aldrich with purity Z99%. The drug was
crystalline in nature as conﬁrmed by the sharp diffraction patterns
of the PXRD result, which is depicted in Fig. 1. Its chemical
structure is presented in Fig. 2. Obtained material was used as
received without further puriﬁcation.
2.2. Methods
2.2.1. Image analysis system (IAS)
Image analysis was used to investigate micro- and macro-spe-
cimens objectively to provide information regarding the micro-
structure, quantity, size, area, shape and phase analysis. Images were
captured using light optical microscope and analyzed using image
analysis software. This technique can be applied in the ﬁeld of ma-
terial science, biological science, pharmaceutical science, etc. Particle
size of fenoﬁbrate was taken by dispersing the sample in water.
2.2.2. DSC
A DSC instrument (821e Mettler-Toledo GmbH) operated with
STARe software version 9.1 and equipped with an intracooler was
used for the thermal transition studies. The instrument was cali-
brated by using indium for temperature and speciﬁc heat. Feno-
ﬁbrate of 3.1540 mg was analyzed under dry nitrogen purge
(50 mL/min) in a sealed pinhole aluminum pan. The sample was
heated from room temperature to 91 °C and held for 3 min; it was
cooled to 50 °C and held for 5 min; and again it was heated to
91 °C. During the entire process a constant heating and cooling
rate of 10 °C/min was used. Thermograms were collected during
heating. Melting point (Tm) was determined as the onset of the
endothermic peak, whereas glass transition temperature (Tg) was
measured as the onset of the glass transition.
2.2.3. Fourier transform infrared (FTIR) spectroscopy
The IR spectra of crystalline and amorphous samples were
collected on a Perkin Elmer (model: Synthesis Monitoring System)Fig. 1. XRPD pattern of crystalline fenoﬁbrate.
Fig. 2. The chemical structure of fenoﬁbrate.and Nicolet instruments corporation USA (Model MAGNA),
respectively.
2.2.4. BDS
Isobaric dielectric measurements at ambient pressure were
carried out using Novo-Control GMBH alpha dielectric spectro-
meter covering a frequency range from 102 to 107 Hz. Tempera-
ture was controlled by using a nitrogen gas cryostat with tem-
perature stability better than 0.1 K. The tested sample was placed
in a measurement capacitor made of stainless steel (diameter:
30 mm, gap: 0.20 mm). Teﬂon was used as the spacer. Dielectric
measurements of fenoﬁbrate were performed after its vitriﬁcation
by fast cooling (10 K/min) from a few degrees above the melting
point (Tm¼354.11 K). The temperature measurements were car-
ried out from 123.15 K to 305.15 K in different steps. However, the
sample did not crystallize during cooling from the melting
temperature.3. Results and discussion
3.1. Particle size
Particle size of fenoﬁbrate was analyzed by IAS and the max-
imum size was found to be 9.95 mm and the minimum was found
to be 1.91 mm. The details of analysis are presented in Table 1.
3.2. Thermal studies
The onset glass transition was observed at 254.15 K, which is
considered as the glass transition temperature (Tg) of fenoﬁbrate.
The onset melting of the sample was observed at 354.11 K, which
is melting temperature (Tm) of the sample. No crystallization was
observed either cooling below Tg or subsequent heating up to
melting point. These results were in good agreement with those
reported by Baird et al. [13] and Zhou et al. [7]. Thermodynamic
quantities obtained from the current work and from the literature
are listed in Table 2. The obtained thermogram of fenoﬁbrate is
presented in Fig. 3.
3.3. Spectroscopic investigation of hydrogen bonding
The spectra of fenoﬁbrate showed different strengths of hy-
drogen bonding (Fig. 4A and B). Two carbonyl peaks were seen in
the crystalline and amorphous fenoﬁbrate, one from the CQO,
and the other from the methyl ester carbonyl group. Crystalline
fenoﬁbrate showed two peaks at 1729.53 cm1 and 1651.48 cm1,
respectively. But in the amorphous form two peaks were seen at
1728.25 cm1 and 1654.22 cm1, respectively. Because of the hy-
drogen bond formation the carbonyl peak position shifted to a
lower wave number. In the amorphous phase, only one carbonyl
group took part in the hydrogen bond formation by a downward
shift of 1.28 cm1. The other peak shifted by value of 2.74 cm1 to
a higher peak position. The upward shifted in the position of the
CQO group suggests that the hydrogen bond in the crystallineTable 1
Class interval and number of particles of fenoﬁbrate.
ID class Class interval (μm) No. of particles
1 0–2 280
2 2–4 777
3 4–6 371
4 6–8 163
5 8–10 79
6 10–12 0
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the above groups capable of classical hydrogen bond formation,
the stretching frequencies of the CH3 were investigated in both the
phases [14,15].
3.4. Molecular dynamics
Dielectric loss spectra (i.e., imaginary part of dielectric per-
mittivity ε″ plotted as a function of frequency f) of fenoﬁbrate is
shown in Fig. 5. Fig. 5A shows the primitive relaxation process
measured above Tg. Tg is deﬁned as the temperature at which the
structural relaxation time (τα) approaches a value of 100 s. Di-
electric loss spectra collected above Tg exhibited the most intense
relaxation i.e., α-relaxation (originating from cooperative reor-
ientational motion of molecules) along with conductivity. The
strength of the dielectric spectra started decreasing from 289.15 K
onwards, indicating that fenoﬁbrate started crystallizing.
Fig. 5B shows the secondary relaxation present below Tg of this
sample. The decrease in dipoles due to crystallization was also
observed from the real part of the permittivity (Fig. 6). Both ε′ and
ε″ were analyzed by using the Win FIT V (3.2) software. The di-
electric spectra were ﬁtted by using the Havriliak–Negami (HN)
function as given below
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where k sums over different relaxation processes, ω is the angular
frequency, τHN is the characteristic relaxation time which is related
to the frequency of maximal loss fmax, Δε is the dielectric strength,
ε1 is the high frequency limit of the real part ε′(ω); αHN and βHNTable 2
Thermodynamic quantities during melting and glass transition of fenoﬁbrate.
Compound MW (g/mol) Tm (K) Tg (K) Ref.
Fenoﬁbrate 360.83 354.11 254.15 This work
354.15 254.15 [13]
353.65 253.15 [7]
Fig. 3. DSC thermogram of fenoﬁbrate obtained during heating/cooling with 10 °C/m
Subsequent cooling of the melt from 364.15 K down to 223.15 K. Following heating of th
transition temperature (Tg) obtained on heating is 254.15 K: at higher temperature therare the symmetric and asymmetric broadenings of loss curve. For
the secondary relaxation process, βHN¼1, then HN function be-
comes the Cole–Cole function.in. Heating of the sample yields Tm¼354.11 K as the onset melting temperature.
e vitriﬁed fenoﬁbrate to a temperature higher than Tm (364.15 K). The onset glass
e is no evidence of crystallization.
Fig. 4. Spectral variations of fenoﬁbrate in CQO stretching vibration region.
(A) crystalline fenoﬁbrate and (B) amorphous fenoﬁbrate.
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coming from the intermolecular motion called Johari–Goldstein
(JG) or (β) relaxation in fenoﬁbrate, coupling model (CM) predic-
tion was applied [16,17]. According to this theoretical tool there is
a good agreement between the JG-relaxation time (τJG) and the
primitive relaxation time (τ0) calculated from Eq. (2)
T T t T 2
n n
JG 0 c
1( ) ( )τ τ τ( ) ≅ ( ) = ( ) ( )α −Fig. 5. Dielectric loss curves obtained for fenoﬁbrate during heating. (A) the pri-
mary relaxation above Tg and (B) the secondary relaxation below Tg.
Fig. 6. Variation of real part of the complex permittivity for fenoﬁbrate with
temperature at different frequencies.where n¼(1βKWW) is the coupling parameter, tc is the crossover
time which represents the crossover from independent to co-
operative motions and equal to 2 ps for small molecular glass
formers.
To describe the non-exponential behavior of α-relaxation the
one-sided Fourier transform of KWW function was also used as
given below
⎡⎣ ⎤⎦t texp / 3KWW KWW)ϕ τ( ) = −( ( )
β
In the frequency domain, the parameter βKWW describes the
shape of the spectra. If βKWW¼1, it denotes symmetric and narrow
relaxation peak, value of βKWW¼0 indicates very broad and
asymmetric peak. For fenoﬁbrate the procedure of ﬁtting the α-
peak by one-side Fourier transform of stretched exponential
function at 257.15 K gives the value of βKWW¼0.70. This means
that experimentally observed structural relaxation peak is asym-
metric and broader than that of classical Debye response. This
indicates the presence of an excess wing (EW). EW is a submerged
process in which true secondary relaxation coming from the in-
termolecular motion is hidden under the prominent α-peak.
For fenoﬁbrate, the value of τ0¼2.643104 s at T¼257.15 K,
corresponds to a frequency of f0¼602.55 Hz. Where f0 is the pri-
mitive relaxation frequency f 1/20 0πτ( = ) and it was found that f0
was far from the maximum of secondary γ-relaxation peak and lay
within the prominent structural relaxation peak. It clearly indicates
that the secondary relaxation β (JG) which is a precursor of the α-
relaxation and originating from the intermolecular motions is hid-
den under the prominent structural α-peak, which means that the
well resolved γ-relaxation is non-JG secondary relaxation. Many
investigations showed that high pressure measurements [18–21] as
well as physical ageing [22,23] can separate the α-peak and EW.
The master curve was constructed in the following way. Several
spectra above Tg were shifted horizontally to superimpose with
that obtained at 257.15 K as shown in Fig. 7. The exponents αHN
and βHN show constant value, i.e., αHNE0.98; βHNE0.57, which
indicates that the shape of the α-peak of fenoﬁbrate does not
change in that region.
Shamblin et al. [24] have suggested that the stretching para-
meter βKWW has a very important role in predicting the stability of
amorphous pharmaceuticals against crystallization. As βKWW de-
creases (the asymmetric distribution of relaxation times becomes
broader) stability would also decrease. By comparing the value of
βKWW of fenoﬁbrate with other APIs (acetaminophen βKWW¼0.79Fig. 7. Super imposed spectra of fenoﬁbrate formed by shifting several spectra
[255.15–281.15 K, ΔT¼2 K] above Tg to overlap the spectrum at 257.15 K. The KWW
ﬁt of the α-peak at 257.15 K yields βKWW¼0.70. The black arrow denotes the po-
sition of primitive relaxation frequency (f0) calculated at 257.15 K using CM
predictions.
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[26], Indapamide βKWW¼0.72 [27], and Ketoprofen βKWW¼0.71
[10]) according to the Shamblin criterion, it was found that sta-
bility of amorphous fenoﬁbrate was lower than that of ketoprofen.
The observed secondary (γ-) relaxation probably originated
from the intramolecular motion of small part of the fenoﬁbrate
molecule (local motions originating from the molecular ﬂuctua-
tions of methyl group). In FTIR spectrum (Fig. 5B) two distinct
bands occurred at 2983.26 and 2939.18 cm1. The ﬁrst band cor-
responded to asymmetrical stretching mode of C–H bonds of
methyl group and the second band arose from the symmetrical
stretching of C–H bonds.
The temperature evolution of the structural relaxation time τα
very often follows the time honored Vogel–Fulcher–Tamman (VFT)
expression, given as below
e 4B T TVF
/ 0τ τ< > = ( )−
with τVF, B, and T0 as parameters.
From VFT ﬁt, we calculated the fragility “m” of fenoﬁbrate by
using Eq. (5):
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VFT ﬁt reveals the value of Tg as 250.56 K. Tg obtained from VFT
ﬁt is in close agreement with that of our DSC study as well as that
of the DSC study done by Baird et al. [13] and Zhou et al. [7]. The
non-Arrhenius behavior of the α-peak gives the measure of the
fragility parameter [28,29]. Strong systems have fragility less than
40 and fragile systems have fragility greater than 75 [1]. Fragile
glass formers are physically unstable compared with the strong
one. Fragility “m” in the case of fenoﬁbrate was estimated as 94.02
and classiﬁed this API as a fragile glass former. Recent studies on
ketoprofen by Shibata et al. [32] showed that there is a strong
correlation between the fragility, boson peak frequency and shearFig. 8. Arrhenius plot of fenoﬁbrate. Filled circles denote α-relaxation, while ﬁlled
squares are for γ-relaxation. The solid lines are ﬁt to the dielectric data using VFT
form for α-process, and Arrhenius equation for γ-process.
Table 3
The ﬁtting parameters for the VFT and Arrhenius equations of fenoﬁbrate.
α-Process, VFT γ-Pro
T0 (K) log τVF D log τ1
209.3271.02 13.5270.17 7.0470.20 14.6modulus; large value of fragility is related to weak boson peak (or
lower boson peak frequency which is caused by small shear
modulus). So fragility is a very important parameter, which gives
an insight to the theory of liquid–glass transition [30]. The
strength parameter D was estimated as 7.04 proving fenoﬁbrate as
a fragile glass former. (Tg–To) was found to be 41.24, and Tm/Tg was
found to be 1.4, and both the methods showed this API belongs to
fragile group. The value of T0 was obtained as 209.32 K. The tem-
perature T0 is often referred to as the Kauzmann temperature TK, a
hypothetical temperature where conﬁgurational entropy of su-
percooled liquid would be equal to entropy of the crystal and
molecular mobility would reduce to the same level as that of the
crystal (strictly speaking the molecular mobility is not zero). For
most of the glassy systems, it lies between 50 and 70 K, below Tg
and it is sufﬁcient to ensure safety storage [4]. Recently Pajula et al.
[31,32] have showed that the stabilization of amorphous drugs can
be achieved by the addition of small molecular weight excipients.
Now we would like to discuss the secondary relaxation coming
from the small part of the fenoﬁbrate molecule which is the
gamma relaxation. The temperature dependence of the relaxation
time of the γ-process shows a linear dependence and can be de-
scribed by the Arrhenius equation
⎡⎣ ⎤⎦E RTexp / 6aτ τ= ( )∞
where τ1 is constant and Ea is the activation energy. The activation
energy for fenoﬁbrate was calculated and obtained as 32.67 kJ/
mol. Fig. 8 shows the relaxation map of fenoﬁbrate. The ﬁtting
parameters of VFT and Arrhenius equations are presented in
Table 3.4. Conclusions
The molecular dynamics of fenoﬁbrate in the glassy and su-
percooled states was studied by different experimental techniques.
Based on the study of the molecular dynamics of fenoﬁbrate in the
glassy and supercooled states by BDS, we are summarising the
important results. Our measurements during cooling with a
cooling rate of 10 K/min from the melt to deep glassy state do not
show any crystallization tendency in fenoﬁbrate, thereby showing
their excellent glass forming ability. Fenoﬁbrate shows structural
(α) relaxation above Tg and one secondary relaxation process be-
low Tg which is characterized as γ-relaxation.
The temperature dependence of α-relaxation times was de-
scribed by single Vogel–Fulcher–Tamman equation. From VFT ﬁts
the glass transition temperature Tg was estimated as 250.56 K. Tg
values calculated from dielectric measurements were found to be
in good agreement with those measured from our DSC experi-
ments as well as with the literature values.
Fragility represents the deviation from the Arrhenius behavior.
It was obtained as 94.02 and we classiﬁed this API as a fragile glass
former. T0 was obtained as 209.32 K. So it is suggested that this API
can provide a shelf life of at least 3–5 years when it is stored in
freezer at a temperature less than T0.
Application of the CM prediction indicated that the Johari–
Goldstein (JG) relaxation is hidden under the prominent structuralcess, Arrhenius
,γ Eγ (kJ/mol) m Tg (K) (BDS)
370.09 32.6770.01 94.02 250.56
U. Sailaja et al. / Journal of Pharmaceutical Analysis 6 (2016) 165–170170relaxation and manifested as an excess wing. The observed sec-
ondary relaxation is characterized as non-JG relaxation (γ relaxation)
and assumed to be originated from the intramolecular degrees of
freedom. The γ-relaxation has an Arrhenius temperature depen-
dence and the activation energy is found to be Eγ¼32.67 kJ/mol. This
drug shows crystallization tendency from 289.15 K onwards during
heating in the dielectric measurements by BDS. The existence of
intermolecular hydrogen bonding was veriﬁed by IR spectroscopy.Acknowledgments
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